CRL vs MEDP
CRL: A global contract research organization providing non-clinical drug development services, research models, and manufacturing solutions across discovery, safety assessment, and biologics testing. MEDP: Medpace is a specialized, full-service clinical contract research organization that helps biopharmaceutical and medical device companies accelerate the development of new therapies through every phase of clinical trials.
Side-by-side fundamentals
| Metric | CRL | MEDP | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $218.70 | $528.12 | |
| Market cap as of 2026-07-23 | $10.6B | $15.0B | |
| P/E as of 2026-07-23 | n/a | 32.69 | |
| PEG as of 2026-07-23 | -0.12 | 2.71 | CRL lower |
| Net margin as of 2026-07-23 | -4.6% | +17.2% | MEDP higher |
| Gross margin as of 2026-07-23 | +34.5% | +29.1% | CRL higher |
| Operating margin as of 2026-07-23 | +1.8% | +21.0% | MEDP higher |
| ROE as of 2026-07-23 | -5.7% | +120.9% | MEDP higher |
| ROA as of 2026-07-23 | -2.5% | +24.8% | MEDP higher |
| Debt / equity as of 2026-07-23 | 0.91 | 0.00 | MEDP lower |
| Revenue growth (YoY) as of 2026-07-23 | +0.1% | +24.2% | MEDP higher |
| Revenue CAGR (3y) SEC XBRL | +0.3% | +20.1% | MEDP higher |
| Beta as of 2026-07-23 | 1.38 | 1.15 | |
| 1-year return as of 2026-07-22 close | +33.9% | +10.5% | CRL higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.